Title: Testing for Vitamin D Deficiency

**Medical Policy**

**Professional**
Original Effective Date: August 26, 2009
Revision Date(s): March 8, 2010; October 26, 2010; January 28, 2011; March 28, 2011; September 29, 2011; December 20, 2011; February 5, 2014; October 1, 2015; June 10, 2016; October 1, 2016; January 25, 2017; February 15, 2018; March 28, 2018; October 1, 2018; February 1, 2019
Current Effective Date: June 10, 2016

**Institutional**
Original Effective Date: August 26, 2009
Revision Date(s): March 8, 2010; October 26, 2010; January 28, 2011; March 28, 2011; September 29, 2011; December 20, 2011; February 5, 2014; October 1, 2015; June 10, 2016; October 1, 2016; January 25, 2017; February 15, 2018; March 28, 2018; October 1, 2018; February 1, 2019
Current Effective Date: June 10, 2016

State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact Blue Cross and Blue Shield of Kansas Customer Service.

The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.

The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.

If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.

<table>
<thead>
<tr>
<th>Populations</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individuals:</td>
<td>Interventions of interest are:</td>
<td>Comparators of interest are:</td>
<td>Relevant outcomes include:</td>
</tr>
<tr>
<td>- Who are asymptomatic without conditions or risk factors for which vitamin D treatment is recommended</td>
<td>- Testing of vitamin D levels</td>
<td>- Routine care without testing vitamin D levels</td>
<td>- Overall survival</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Test validity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Symptoms</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Morbid events</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Treatment-related morbidity</td>
</tr>
</tbody>
</table>
DESCRIPTION
Vitamin D, also known as calciferol, is a fat-soluble vitamin that has a variety of physiologic effects, most prominently in calcium homeostasis and bone metabolism. In addition to the role it plays in bone metabolism, other physiologic effects include inhibition of smooth muscle proliferation, regulation of the renin-angiotensin system, decrease in coagulation, and decrease in inflammatory markers.

OBJECTIVE
The objective of this policy is to examine whether testing for vitamin D deficiency in asymptomatic patients improves health outcomes.

BACKGROUND

Vitamin D
Vitamin D, also known as calciferol, is a fat-soluble vitamin that has a variety of physiologic effects, most prominently in calcium homeostasis and bone metabolism. In addition to the role it plays in bone metabolism, other physiologic effects include inhibition of smooth muscle proliferation, regulation of the renin-angiotensin system, decrease in coagulation, and decrease in inflammatory markers.1

Vitamin D Levels
Vitamin D deficiency is best assessed by measuring serum levels of 25-hydroxyvitamin D. However, there is no consensus on the minimum vitamin D level or on the optimal serum level for overall health. A 2010 Institute of Medicine (IOM) report concluded that a level of 20 ng/mL is sufficient for most healthy adults.2

Some experts, such as the National Osteoporosis Foundation and the American Geriatrics Society, recommend a higher level (30 ng/mL).2

Vitamin D deficiency, as defined by suboptimal serum levels, is common in the United States. In the National Health and Nutrition Examination Survey (NHANES) survey covering the period of 2000-2004, a total of 30% of individuals over the age of 12 had 25-hydroxyvitamin D levels less than 20 ng/mL.3

Vitamin D deficiency occurs most commonly as a result of inadequate dietary intake coupled with inadequate sun exposure. Evidence from the National Nutrition Monitoring System (NNMS) and the NHANES has indicated that the average consumption is below recommended levels of intake. Yetley3 estimated that average daily intake for U.S. adults ranged from 228 to 335 IU/d, depending on gender and ethnicity. This is below the average daily requirement, estimated by IOM (400 IU/d for healthy adults), and well below IOM’s required daily allowance, which was estimated to be 600 IU for nonelderly adults and 800 IU for elderly adults.

Vitamin D deficiency may occur less commonly for other reasons. Kidney or liver disease can cause deficiency as a result of impaired conversion of inactive vitamin D to
its active products. In rare situations, there is vitamin D resistance at the tissue level, which causes a functional vitamin D deficiency despite “adequate” serum levels.

The safe upper level for serum vitamin D is also not standardized. The IOM report\(^2\) concluded that there is potential harm associated with levels greater than 50 ng/mL and recommended that serum levels be maintained in the 20 to 40 ng/mL range.

However, other conclusions on this point have differed. The Agency for Healthcare Research and Quality (AHRQ) systematic review on vitamin D and bone health concluded that “There is little evidence from existing trials that vitamin D above current reference intakes is harmful.”\(^4\)

The Women’s Health Initiative (WHI) concluded that hypercalcemia and hypercalciuria in patients receiving calcium and vitamin D were not associated with adverse clinical events.\(^5\) The WHI did find a small increase in kidney stones for women aged 50 to 79 years who received vitamin D and calcium.

Associations of vitamin D levels with various aspects of health have been noted over the last several decades,\(^6-10\) and these findings have led to the question of whether supplementation improves health outcomes. For example, a relationship between vitamin D levels and overall mortality has been reported in most observational studies examining this relationship.\(^11,12\) Mortality is lowest at vitamin D levels D in the 25 to 40 nmol/L range. At lower levels of serum vitamin D, mortality increases steeply, and overall mortality in the lowest quintile was more than 3 times that in the middle quintiles. Theodoratou et al (2014) identified 107 systematic reviews of observational studies examining the association between vitamin D levels and more than 100 different outcomes.\(^13\)

Vitamin D Replacement
The IOM document recommended reference values for intake of vitamin D and serum levels, based on available literature and expert consensus.\(^2\) Recommended daily allowances are 600 IU/d for individuals between 1 and 70 years of age and 800 IU/d for individuals older than 70 years.

Estimates of vitamin D requirements are complicated by the many other factors that affect serum levels. Sun exposure is the most prominent, because individuals can meet their vitamin D needs entirely through adequate sun exposure. Other factors such as age, skin pigmentation, obesity, physical activity, and nutritional status also affect vitamin D levels and can result in variable dietary intake requirements to maintain adequate serum levels.

Excessive intake of vitamin D can have toxic effects. These toxic effects are usually due to hypercalcemia and may include confusion, weakness, polyuria, polydipsia, anorexia, and vomiting. In addition, high levels of vitamin D may promote calcium deposition and
has the potential to exacerbate conditions such as calcium kidney stones and atherosclerotic vascular disease.

IOM defined 3 parameters of nutritional needs for vitamin D, on the assumption of minimal sun exposure. They were the estimated average requirement, defined as the minimum intake required to maintain adequate levels; the recommended daily allowance, defined as the optimal dose for replacement therapy; and the upper-level intake, defined as the maximum daily dose to avoid toxicity. These recommendations are summarized in Table 1.

### Table 1. Institute of Medicine Recommendations for Vitamin D Dietary Intake

<table>
<thead>
<tr>
<th>Patient Group</th>
<th>Estimated Average Requirement, IU/d</th>
<th>Recommended Daily Allowance, IU/d</th>
<th>Upper Limit Intake, IU/d</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-3 years old</td>
<td>400</td>
<td>600</td>
<td>2500</td>
</tr>
<tr>
<td>4-8 years old</td>
<td>400</td>
<td>600</td>
<td>3000</td>
</tr>
<tr>
<td>9-70 years old</td>
<td>400</td>
<td>600</td>
<td>4000</td>
</tr>
<tr>
<td>&gt;70 years old</td>
<td>400</td>
<td>800</td>
<td>4000</td>
</tr>
</tbody>
</table>

### REGULATORY STATUS

The U.S. Food and Drug Administration has cleared a number of immunoassay in vitro diagnostic devices for the quantitative measurement of total 25(OH)D through the 510(k) process.

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests (LDTs) must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Lab tests for vitamin D are available under the auspices of CLIA. Laboratories that offer LDTs must be licensed by CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

### POLICY

A. Testing for vitamin D deficiency may be considered **medically necessary** in patients with signs and/or symptoms of vitamin D deficiency or toxicity (see Policy Guidelines) when one of the high-risk factors is present:

1. chronic kidney disease, stage ≥3
2. granulomatous diseases
3. parathyroid disorders
4. cirrhosis/chronic liver disease
5. malabsorption states
6. chronic use of anticonvulsant medications or corticosteroids
7. osteomalacia
8. osteopenia
9. osteoporosis
10. rickets
11. vitamin D deficiency, on replacement
12. hypo- or hypercalcemia
13. obstructive jaundice/biliary tract disease
14. osteogenesis imperfecta
15. osteosclerosis/osteopetrosis

B. Testing vitamin D levels in asymptomatic patients may be considered **medically necessary** in the following patient populations:

1. Individuals who have risk factors for vitamin D deficiency (as listed in Item A above)
2. Institutionalized patients (see Policy Guidelines)

C. Testing vitamin D levels in asymptomatic patients is considered **not medically necessary** when the above criteria are not met.

D. Routine screening for vitamin D deficiency is **not medically necessary**.

Policy Guidelines
1. Signs and symptoms of vitamin D deficiency are largely manifested by changes in bone health and biochemical markers associated with bone production and resorption. In most cases, a clinical diagnosis of an abnormality in bone health (eg, rickets, osteomalacia, osteoporosis) will lead to a decision to test vitamin D levels. Symptoms related to the clinical condition may be present, such as pain or low-impact fractures, but these symptoms are usually not indications for testing prior to a specific diagnosis. Some biochemical markers of bone health may indicate an increased risk for vitamin D deficiency, and testing of vitamin D levels may therefore be appropriate. These biochemical markers include unexplained abnormalities in serum calcium, phosphorous, alkaline phosphatase, and/or parathyroid hormone.

2. Signs and symptoms of vitamin D toxicity (hypervitaminosis D) generally result from induced hypercalcemia. Acute intoxication can cause symptoms of confusion, anorexia, vomiting, weakness, polydipsia, and polyuria. Chronic intoxication can cause bone demineralization, kidney stones, and bone pain.

3. “Institutionalized” as used herein refers to patients who reside at long-term facilities where some degree of medical care is provided. These circumstances and facilities can include long-term hospital stays, nursing homes, assisted living facilities, and similar environments.

4. The need for repeat testing may vary by condition. A single test may be indicated for diagnostic purposes; a repeat test may be appropriate to determine whether supplementation has been successful in restoring normal serum levels. More than 1 repeat test may be indicated occasionally, such as in cases where supplementation has not been successful in restoring levels (another example might include an instance in which continued or recurrent signs and symptoms
may indicate ongoing deficiency, and/or when inadequate absorption or noncompliance with replacement therapy is suspected).

**RATIONALE**
This evidence review was created in September 2015 with literature review through October 18, 2018.

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

**Vitamin D Deficiency**

**Clinical Context and Test Purpose**
The purpose of testing of vitamin D levels is to provide a treatment option that is an alternative to or an improvement on existing therapies in patients who are asymptomatic without conditions or risk factors for which vitamin D treatment is recommended.

The question addressed in this evidence review is: Does testing for vitamin D deficiency in asymptomatic patients improve the net health outcome?

The following PICOTS were used to select literature to inform this review.

**Patients**
The relevant population of interest is individuals who are asymptomatic without conditions or risk factors for which vitamin D treatment is recommended.

**Interventions**
The therapy being considered is testing of vitamin D levels.

**Comparators**
The following practice is currently being used to manage vitamin D deficiency: routine care without testing for vitamin D deficiency. Routine care may include recommendations for increased ultraviolet B exposure, dietary intake of vitamin D, or vitamin D supplementation even in the absence of known vitamin D deficiency.

**Outcomes**
The general outcomes of interest are overall survival, test validity, symptoms, morbid events, and treatment-related morbidity.
Timing
The length of time needed to correct subclinical vitamin D deficiency and improve outcomes is unknown and probably varies between outcomes.

Setting
Patients with vitamin D deficiency are managed by primary care providers in an outpatient setting.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

- The study population represents the population of interest. Eligibility and selection are described.
- The test is compared with a credible reference standard.
- If the test is intended to replace or be an adjunct to an existing test; it should also be compared with that test.
- Studies should report sensitivity, specificity, and predictive values. Studies that completely report true- and false-positive results are ideal. Studies reporting other measures (eg, ROC, AUROC, c-statistic, likelihood ratios) may be included but are less informative.
- Studies should also report reclassification of diagnostic or risk category.

Analytic Framework
Figure 1 summarizes the approach to this evidence review. The diagram demonstrates the framework for how vitamin D testing affects outcomes. Using this framework, the main question is whether testing individuals for vitamin D deficiency improves outcomes.

Figure 1. Analytic Framework
Based on this analytic framework, the most relevant studies for showing clinical utility of vitamin D testing are trials that directly compare care including testing vitamin D levels against care without testing vitamin D levels. Should vitamin D screening in nonsymptomatic, general population be shown to be effective, guidelines would then be needed to establish criteria for screening, screening intervals, and appropriate follow-up for positive tests. Indirect evidence of the utility of vitamin D testing would include evidence of the effectiveness of supplementation from trials testing supplementation to no supplementation in patients who are vitamin D deficient. Many of the existing randomized controlled trials (RCTs), including the largest trial (Women’s Health Initiative), did not test vitamin D levels prior to treatment. Rather, they treated all patients enrolled regardless of vitamin D levels. Results of some of the main systematic reviews that take this approach will be reviewed, but this evidence is indirect and must be extrapolated from treatment of all patients to treatment of patients who are vitamin D deficient.

**Technically Reliable**
Assessment of technical reliability focuses on specific tests and operators and requires review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

**Clinically Valid**
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

There is no consensus on how to define vitamin D deficiency or inadequacy, and there is no accepted reference standard. Available cutoffs for deficiency are neither standardized nor based on rigorous scientific studies.[14]

Therefore, despite the availability of many tests that measure total serum 25-hydroxyvitamin D (25(OH)D) levels, their sensitivities and specificities for detecting clinically important deficiency are currently unknown.

**Clinically Useful**
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

No RCTs were found that evaluated clinical outcomes or harms in patients tested for vitamin D deficiency vs not tested for vitamin D deficiency. In the absence of direct evidence of the utility of testing, evidence of the effectiveness of vitamin D supplementation could indirectly support the utility of testing by identifying a group of patients in which baseline serum 25(OH)D is a predictor of supplement effect so that testing might be useful.

A large number of RCTs have evaluated the impact of vitamin D supplementation on outcomes. Theodoratou et al (2014) identified 87 meta-analyses of RCTs on vitamin D supplementation[13]; there were 21 meta-analyses on skeletal health, 7 on metabolic disease, 4 on pediatric outcomes, 3 on cardiovascular disease, 3 on pregnancy-related outcomes, and 18 on other outcomes. Because of the large literature base, this review of evidence will focus on the largest and most recent systematic reviews and meta-analyses of RCTs. Individual trials will be reviewed
separately if they were not included in the meta-analyses or if particular features need highlighting.

**Skeletal Health**

**Systematic Reviews:** Numerous systematic reviews and meta-analyses of RCTs have been published evaluating the impact of vitamin D supplementation on skeletal health outcomes. Relevant health outcomes considered for this evidence review include fractures and falls. Studies that looked at the bone mineral density and/or other physiologic measures of bone health were not included. Table 2 summarizes the results of systematic reviews performing quantitative meta-analyses on the relevant outcomes.

Among the trials included in the meta-analyses, few were large studies; most were small or moderate in size and limited by a small number of outcomes events. Doses of vitamin D varied widely from 400 to 4800 IU/d; treatment and follow-up durations varied from 2 months to 7 years. Some studies limited enrollment to participants with low serum vitamin D. Most studies excluded institutionalized patients, but some included them. There was inconsistency in the results, especially for studies of fracture prevention, as evidenced by the relatively large degree of heterogeneity among studies.

**Table 2.** Systematic Reviews Assessing the Impact of Vitamin D Supplementation on Skeletal Health

<table>
<thead>
<tr>
<th>Study</th>
<th>Outcome</th>
<th>No. of Studies</th>
<th>No. of Participants</th>
<th>I^2, %a</th>
<th>RR for Outcome (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LeBlanc et al (2015)[15]</td>
<td>Any fracture</td>
<td>5</td>
<td>3551</td>
<td>32</td>
<td>0.98 (0.82 to 1.16)</td>
</tr>
<tr>
<td></td>
<td>Hip fracture</td>
<td>4</td>
<td>1619</td>
<td>46</td>
<td>0.96 (0.72 to 1.29)</td>
</tr>
<tr>
<td></td>
<td>Falls: total</td>
<td>5</td>
<td>1677</td>
<td>70</td>
<td>0.84 (0.69 to 1.02)</td>
</tr>
<tr>
<td></td>
<td>Falls: person</td>
<td>5</td>
<td>1809</td>
<td>64.5</td>
<td>0.66 (0.50 to 0.88)</td>
</tr>
<tr>
<td>Cranney et al (2011)[4] ; AHRQ</td>
<td>Any fracture</td>
<td>14</td>
<td>58,712</td>
<td>48.3</td>
<td>0.90 (0.81 to 1.01)</td>
</tr>
<tr>
<td></td>
<td>Hip fracture</td>
<td>8</td>
<td>46,072</td>
<td>16.2</td>
<td>0.83 (0.68 to 1.0)</td>
</tr>
<tr>
<td></td>
<td>Falls</td>
<td>9</td>
<td>9262</td>
<td>0</td>
<td>0.84 (0.76 to 0.93)</td>
</tr>
<tr>
<td>Avenell et al (2009)[16]</td>
<td>All fractures</td>
<td>10</td>
<td>25,016</td>
<td>NR</td>
<td>1.01 (0.93 to 1.09)</td>
</tr>
<tr>
<td></td>
<td>Hip fractures</td>
<td>9</td>
<td>24,749</td>
<td>NR</td>
<td>1.15 (0.99 to 1.33)</td>
</tr>
<tr>
<td></td>
<td>Vertebral fracture</td>
<td>5</td>
<td>9138</td>
<td>NR</td>
<td>0.90 (0.97 to 1.1)</td>
</tr>
<tr>
<td>Bischoff-Ferrari et al (2009)[17]</td>
<td>Nonvertebral fracture</td>
<td>5</td>
<td>7130</td>
<td>NR</td>
<td>0.79 (0.63 to 0.99)</td>
</tr>
<tr>
<td>Palmer et al (2009)[18]</td>
<td>All fractures (CKD-RD)</td>
<td>4</td>
<td>181</td>
<td>NR</td>
<td>1.0 (0.06 to 15.41)</td>
</tr>
<tr>
<td></td>
<td>700-800 IU/d</td>
<td>3</td>
<td>5572</td>
<td>NR</td>
<td>0.74 (0.61 to 0.88)</td>
</tr>
<tr>
<td></td>
<td>400 IU/d</td>
<td>2</td>
<td>3722</td>
<td>NR</td>
<td>1.15 (0.88 to 1.50)</td>
</tr>
<tr>
<td></td>
<td>Nonvertebral fracture</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>700-800 IU/d</td>
<td>5</td>
<td>6098</td>
<td>NR</td>
<td>0.77 (0.68 to 0.87)</td>
</tr>
<tr>
<td></td>
<td>400 IU/d</td>
<td>2</td>
<td>3722</td>
<td>NR</td>
<td>1.03 (0.86 to 1.24)</td>
</tr>
</tbody>
</table>

AHRQ: Agency for Healthcare Research and Quality; CI: confidence interval; CKD-RD: chronic kidney disease on renal dialysis; NR: not reported; RCT: randomized controlled trial; RR: relative risk. A Heterogeneity value.
Cranney et al (2011) conducted a review for the Agency for Healthcare Research and Quality (AHRQ) on the effectiveness and safety of vitamin D in relation to bone health.[4]

Reviewers concluded that:

- The evidence on reduction in fractures was inconsistent. The combined results of trials using vitamin D3 with calcium were consistent with a benefit on fractures, although the benefit was primarily found in the subgroup of elderly institutionalized women, which was a subgroup not included in this review.
- The evidence on a benefit in fall risk was also inconsistent. The results showed benefit in subgroups of postmenopausal women and in trials that used vitamin D in combination with calcium. There was a reduction in fall risk with vitamin D when 6 trials that adequately ascertained falls were combined.

A meta-analysis of double-blind RCTs by Bischoff-Ferrari et al (2005) estimated the benefit of vitamin D supplementation on fracture risk and examined the dose-response relation between vitamin D and outcomes.[19]

Based on a meta-analysis of 5 RCTs that used high-dose vitamin D, reviewers concluded that supplementation at 700 to 800 IU/d reduced the incidence of hip fractures by 26%, and reduced any nonvertebral fracture by 23%. In this same review, based on the results of 2 RCTs, lower doses of vitamin D at 400 IU/d did not significantly reduce the fracture risk.

**Randomized Controlled Trials**

An RCT not included in most of the systematic reviews (by Sanders et al [2010][20]) reported results inconsistent with some of the previous trials and conclusions of meta-analyses. In this trial, 2256 community-dwelling elderly individuals at high risk for falls were treated with high-dose vitamin D500,000 IU orally once per year for 3 to 5 years. There was a 15% increase in falls for the group treated with vitamin D (p=0.03) and a 26% increase in fractures (p=0.02). In addition, there was a temporal relation to the increase in fall risk, with the greatest risk in the period immediately after vitamin D administration. It is unclear whether the specific regimen used in this study (eg, high-dose vitamin D once/year) was responsible for the different results seen in this study compared with prior research.

**Section Summary: Skeletal Health**

Numerous RCTs and meta-analyses of RCTs have been published on the effect of vitamin D supplementation on skeletal health. The most direct evidence consists of trials that selected patients for vitamin D deficiency and randomize patients to vitamin D or placebo. A meta-analysis of these trials showed no reduction in fractures and an uncertain reduction in falls. In meta-analyses that treated all patients regardless of vitamin D levels, there are inconsistent findings on the effect of supplementation on fractures and falls. There is some evidence that subgroups (eg, elderly women) may benefit from supplementation and that higher doses may provide a benefit whereas lower doses do not; however, very high doses may increase the risk of falls. Therefore, the evidence does not convincingly demonstrate an improvement in skeletal health outcomes with vitamin D supplementation.
Cardiovascular Disease
A large number of trials have reported on the impact of vitamin D supplementation on cardiovascular events. A number of systematic reviews have examined the relation between vitamin D and cardiovascular outcomes.

Elamin et al (2011) published a systematic review and meta-analysis evaluating cardiovascular outcomes.[21]

It included 51 trials that used various forms of vitamin D with or without calcium. There was minimal heterogeneity among the studies. Combined analysis showed no significant impact on cardiovascular death (relative risk [RR], 0.96; 95% confidence interval [CI], 0.93 to 1.0), myocardial infarction (RR=1.02; 95% CI, 0.93 to 1.13), or stroke (RR=1.05; 95% CI, 0.88 to 1.25). No significant effects were found on the physiologic outcomes of lipids, glucose, or blood pressure.

A systematic review by Pittas et al (2010) assessed 5 RCTs evaluating the impact of vitamin D supplementation on incident cardiovascular disease.[22]

None of the 5 trials reported a significant reduction in cardiovascular outcomes in the vitamin D group. Combined analysis of these trials found a RR for cardiovascular outcomes of 1.08 (95% CI, 0.99 to 1.19) in the vitamin D group.

An AHRQ report by Chung et al (2009) concluded that[23]:

- The evidence on the impact of vitamin D on cardiovascular outcomes is inconsistent, and conclusions are difficult to make because of the marked heterogeneity of the evidence.
- The RCTs that have evaluated the impact of vitamin D on cardiovascular outcomes use cardiovascular events as a secondary outcome, not as a prespecified primary outcome.
- These analyses have been hampered by low numbers of cardiovascular events and imperfect methods for ascertainment of cardiovascular events.

Wang et al (2008) also performed a systematic review of whether vitamin D and calcium prevent cardiovascular events.[24]

Eight RCTs of vitamin D supplementation in the general population evaluated cardiovascular outcomes as a secondary outcome. A combined analysis of studies that used high-dose vitamin D supplementation (1000 IU/d) found a 10% reduction in cardiovascular events, but this reduction was not statistically significant (RR=0.90; 95% CI, 0.77 to 1.05). When studies that combined vitamin D plus calcium supplementation were included, there was no trend toward a benefit (RR=1.04; 95% CI, 0.92 to 1.18).

Section Summary: Cardiovascular Disease
The available evidence does not support a benefit of vitamin D supplementation on cardiovascular events. Numerous RCTs have assessed this outcome—however, in most studies, it is a secondary outcome with a limited number of events, thus limiting the power to detect a difference. Furthermore, it is difficult to separate the impact of vitamin D from the impact of calcium in many of these studies. It is common to use vitamin D and calcium supplementation together. Research has also highlighted a potential increase in cardiovascular outcomes associated with calcium supplementation.[25]
Thus, if there are beneficial effects of vitamin D, they may be obscured or attenuated by concomitant administration of calcium supplements. Another possibility is that vitamin D and calcium act synergistically, promoting either a greater protective effect against cardiovascular disease or an increase in cardiovascular risk.

**Hypertension**
A systematic review by Pittas et al (2010) included 10 intervention trials that evaluated the relation between vitamin D and hypertension.[22]

Most did not report a decrease in incident hypertension associated with vitamin D supplementation. The largest trial with the longest follow-up was the Women’s Health Initiative, which included over 36000 patients.[26]

The Women’s Health Initiative trial did not show a reduction in the incidence of hypertension in vitamin D treated individuals. There was a small, nonsignificant decrease in systolic blood pressure for patients in the vitamin D group (-1.9 mmHg; 95% CI, -4.2 to 0.4 mm Hg) and no change in diastolic blood pressure (-0.1 mm Hg; 95% CI, -0.7 to 0.5 mm Hg).

**Cancer**
*Systematic Reviews:* A Cochrane systematic review by Bjelakovic et al (2014) assessed the benefits and harms of vitamin D supplementation on the prevention of cancer in adults.[27]

Reviewers included 18 RCTs (50,623 participants) that compared vitamin D at any dose, duration, and route of administration with placebo or no intervention in healthy adults or diagnosed with a specific disease. Cancer occurred in 1927 (7.6%) of 25,275 participants assigned to vitamin D and in 1943 (7.7%) of 25348 participants assigned to control interventions (RR=1.00; 95% CI, 0.94 to 1.06) based on GRADE moderate quality evidence. There was no substantial difference in the effect of vitamin D on cancer in subgroup analyses of trials only including participants with vitamin D levels less than 20 ng/mL at enrollment compared with trials including participants with vitamin D levels of 20 ng/mL or greater at enrollment. Vitamin D3 combined with calcium was associated with increased nephrolithiasis (RR=1.17; 95% CI, 1.03 to 1.34).

An AHRQ report by Newberry et al (2014) summarized the evidence on vitamin D supplementation and cancer outcomes.[28]

Based on a limited number of RCTs, the following conclusions were made:
- One RCT reported no effect of vitamin D on overall cancer mortality in healthy postmenopausal women.
- One RCT reported no effect of vitamin D on overall cancer mortality for elderly men or women.

The evidence on the association between vitamin D levels and cancer was reviewed by the Institute of Medicine in 2011, with the following conclusions[2]:
- A small number of studies addressed this question and they showed a lack of consistency in associations between vitamin D intake, or levels, and all cancer mortality.
- Most available RCTs did not have cancer as a prespecified primary outcome; thus, the validity of the data was less than optimal.
Currently, the evidence was insufficient to form conclusions about the association of vitamin D with cancer.

Randomized Controlled Trials
Lappe et al (2017) reported the results of the Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women (CAPS). CAPS was a double-blind, placebo-controlled randomized trial of vitamin D3 and calcium including 2303 healthy, postmenopausal, noninstitutionalized women in 31 rural counties in Nebraska.[29]

The women were randomized to vitamin D 2000 IU/d plus calcium 1500 mg/d (n=1156) or matching placebos (n=1147) for a period of 4 years. The primary outcome was time to first diagnosis of any type of cancer (excluding nonmelanoma skin cancers) over 4 years. The trial was conducted from June 2009 to August 2015. A total of 2064 (90%) women completed the 4 years of study and 2197 (95%) provided at least 6 months of follow-up data. Mean baseline 25(OH)D level was 32.8 ng/mL. Mean achieved 25(OH)D levels during follow-up were 43.6 ng/mL (95% CI, 42.9 to 44.3 ng/mL) in the vitamin D3 plus calcium group and 31.6 ng/mL (95% CI, 31.0 to 32.2 ng/mL) in the placebo group. Ninety-three women in the vitamin D3 plus calcium group discontinued their intervention early due to adverse events compared with 76 in the placebo group. Kaplan-Meier estimated cancer incidence was 4.2% (95% CI, 3.2% to 5.6%) in the vitamin D3 plus calcium group and 6.0% (95% CI, 4.8% to 7.6%) in the placebo group (hazard ratio [HR], 0.70; 95% CI, 0.47 to 1.02; p=0.06). In a post hoc analysis of achieved 25(OH)D levels, the estimated HR for cancer incidence for 25(OH)D levels between 30 ng/mL and 55 ng/mL compared with 30 ng/mL was 0.65 (95% CI, 0.44 to 0.97). Breast cancer was the most common first diagnosed cancer, with 16 diagnoses in the vitamin D3 plus calcium group and 23 diagnoses in the placebo group. There were no serious supplement-related adverse events. Because of the study design, the separate effects of interventional calcium and vitamin D3 cannot be assessed. The women in this trial had higher baseline 25(OH)D levels than the U.S. population based on the U.S. National Health and Nutrition Examination Surveys and therefore might not be representative of the target population. Moreover, the participants were almost entirely non-Hispanic, white women, which limits generalizability to men and other racial/ethnic groups. The trial was powered to detect a 50% risk reduction; however, a 50% reduction is unlikely to be the minimally clinically important difference. Smaller risk reductions in all-cause cancer (eg, the 30% estimated reduction) would also be clinically important.

Baron et al (2015) published results of a 2×2 factorial RCT of supplementation with vitamin D and/or calcium for the prevention of colorectal adenomas.[30]

The trial enrolled 2259 patients with recently diagnosed adenomas and no known colorectal polyps remaining after complete colonoscopy. Patients received treatment and continued follow-up for 3 to 5 years and the primary outcome was adenomas diagnosed through colonoscopy. Overall, 1301 (43%) of patients had 1 or more adenomas. The RRs for recurrent adenomas were adjusted for age, clinical center, anticipated surveillance interval (3 or 5 years), sex, type of randomization, and a number of baseline adenomas. The adjusted RR for recurrent adenomas was 0.99 (95% CI, 0.89 to 1.09) with vitamin D vs no vitamin D. The findings for advanced adenomas were similar. There were few serious adverse events, and rates of hypercalcemia did not differ between vitamin D and no vitamin D.
Section Summary: Cancer
Many RCTs have been examined the effect of vitamin D supplementation on cancer outcomes, although cancer was not the prespecified primary outcome in most. The CAPS trial was designed with all-cause cancer as the primary outcome. The current evidence does not demonstrate that vitamin D supplementation reduces the incidence of cancer.

Asthma
Systematic Reviews: Several systematic reviews of vitamin D supplementation for prevention of asthma exacerbations have been published. Three recent reviews are summarized in Tables 3 and 4. Thirteen unique RCTs were included in the 3 systematic reviews (see Table 5). Reviews by Jolliffe et al (2017) and Martineau et al (2016) concluded that the RCTs were generally at low risk of bias. The RCTs included children and adults, as well as variable doses of vitamin D, routes and lengths of administration, and variable levels of asthma severity. The RCTs also included patients with variable baseline 25(OH)D levels and patients were not generally selected by baseline 25(OH)D. The Jolliffe (2017) and Martineau (2016) reviews found that vitamin D supplementation reduced the rate (or proportion) of asthma exacerbations requiring treatment with systemic corticosteroids. The reviews by Martineau et al (2016) and Luo et al (2015) found that vitamin D had no effect on Asthma Control Test scores, forced expiratory volume in 1-second outcomes, or rates of adverse events. The review by Jolliffe et al (2017) used individual participant data and was, therefore, able to test for patient-level subgroup effects. For the outcome of “rate of asthma exacerbations treated with systemic corticosteroids,” the protective effect of vitamin D was larger in patients with a baseline 25(OH)D levels of less than 25 nmol/L (rate ratio, 0.33; 95% CI, 0.11 to 0.98) compared with patients who had higher a baseline 25(OH)D levels (rate ratio, 0.77; 95% CI, 0.58 to 1.03). However, the subgroup by treatment group interaction was not statistically significant (p=0.25).

Table 3. Characteristics of Systematic Review Assessing Vitamin D and Asthma

<table>
<thead>
<tr>
<th>Study; Trial</th>
<th>Dates</th>
<th>Trials</th>
<th>Participants</th>
<th>N</th>
<th>Design</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jolliffe et al (2017)</td>
<td>To Oct 2016</td>
<td>8</td>
<td>People with asthma, all ages, and baseline 25(OH)D levels included</td>
<td>1078</td>
<td>Randomized, double-blind, placebo-controlled</td>
<td>15 wk to 12 mo</td>
</tr>
<tr>
<td>Martineau et al (2016)</td>
<td>To Jan 2016</td>
<td>9</td>
<td>People with asthma, all ages, and baseline 25(OH)D levels included</td>
<td>1093</td>
<td>Randomized, double-blind, placebo-controlled</td>
<td>4-12 mo</td>
</tr>
<tr>
<td>Luo et al (2015)</td>
<td>1946-2015</td>
<td>7</td>
<td>People with asthma, all ages, and baseline 25(OH)D levels included</td>
<td>903</td>
<td>RCT</td>
<td>9 wk to 12 mo</td>
</tr>
</tbody>
</table>

RCT: randomized controlled trial; 25-(OH)D: 25-hydroxyvitamin D.

Table 4. Results of Systematic Review Assessing Vitamin D and Asthma

<table>
<thead>
<tr>
<th>Study; Trial</th>
<th>Asthma Exacerbation</th>
<th>Asthma Exacerbation Requiring SCS</th>
<th>ACT Score</th>
<th>FEV1 Proportion of Patients With AEs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jolliffe et al (2017)</td>
<td>868</td>
<td>955</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Total N</td>
<td>955</td>
<td>0.55 to 1.10</td>
<td>0.56 to 0.97</td>
<td>955</td>
</tr>
<tr>
<td>Pooled effect</td>
<td>HR=0.78</td>
<td>RR=0.74</td>
<td>OR=0.87d</td>
<td></td>
</tr>
<tr>
<td>95% CI</td>
<td>0.55 to 1.10</td>
<td>0.56 to 0.97</td>
<td>0.46 to 1.63</td>
<td></td>
</tr>
<tr>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Martineau et al (2016)</td>
<td>868</td>
<td>955</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Total N</td>
<td>955</td>
<td>0.55 to 1.10</td>
<td>0.56 to 0.97</td>
<td>955</td>
</tr>
<tr>
<td>Pooled effect</td>
<td>HR=0.78</td>
<td>RR=0.74</td>
<td>OR=0.87d</td>
<td></td>
</tr>
<tr>
<td>95% CI</td>
<td>0.55 to 1.10</td>
<td>0.56 to 0.97</td>
<td>0.46 to 1.63</td>
<td></td>
</tr>
<tr>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Asthma Exacerbation</td>
<td>Asthma Exacerbation Requiring SCS</td>
<td>ACT Score</td>
<td>FEV1</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>---------------------</td>
<td>----------------------------------</td>
<td>-----------</td>
<td>------</td>
</tr>
<tr>
<td>Total N</td>
<td>999</td>
<td>963</td>
<td>713</td>
<td>387</td>
</tr>
<tr>
<td>Pooled effect</td>
<td>OR=0.53</td>
<td>OR=0.39a</td>
<td>Diff = -0.08</td>
<td>Diff=0.48%b</td>
</tr>
<tr>
<td>95% CI</td>
<td>0.28 to 0.99, favoring vitamin D</td>
<td>0.19 to 0.78, favoring vitamin D</td>
<td>-0.70 to 0.54</td>
<td>0.93 to 1.89</td>
</tr>
<tr>
<td>I2</td>
<td>65%</td>
<td>0%</td>
<td>21%</td>
<td>0%</td>
</tr>
<tr>
<td>Pooled effect</td>
<td>OR=0.66</td>
<td>NR</td>
<td>Diff = -0.05</td>
<td>Diff = -0.02c</td>
</tr>
<tr>
<td>95% CI</td>
<td>0.32 to 1.37</td>
<td></td>
<td>-0.30 to 0.20</td>
<td>-0.15 to 0.11</td>
</tr>
<tr>
<td>I2</td>
<td>81%</td>
<td>NA</td>
<td>0%</td>
<td>0%</td>
</tr>
</tbody>
</table>

ACT: Asthma Control Test; AE: adverse event; Diff: difference; FEV1: forced expiratory volume in 1 second; HR: hazard ratio; NA: not applicable; NR: not reported; OR: odds ratio; RR: relative risk; SCS: systemic corticosteroid.

a Outcome was proportion with >=1 exacerbations.

b FEV1, % predicted.

c At 12 months.

d Serious adverse events.

**Table 5. Comparison of Randomized Controlled Trials Included in the Systematic Reviews**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Worth et al (1994)[34]</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Majak et al (2009)[35]</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Urashima et al (2010)[36]</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Majak et al (2011)[37]</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Lewis et al (2012)[38]</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Castro et al (2014)[40]</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Yadav et al (2014)[41]</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>De Groot et al (2015)[42]</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Martineau et al (2015)[43]</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Tachimoto et al (2016)[44]</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Jensen et al (2016)[45]</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Kerley et al (2016)[46]</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
</tbody>
</table>

**Randomized Controlled Trials**

An RCT of prenatal supplementation in 881 pregnant women at high risk of having children with asthma was published in 2016.[47]

Women between gestational ages of 10 and 18 weeks were randomized to daily vitamin D 4000 IU plus a multivitamin containing vitamin D 400 IU (4400 IU group) or daily placebo vitamin D plus a multivitamin containing vitamin D 400 IU (400 IU group). Coprimary outcomes were (1) parental report of physician-diagnosed asthma or recurrent wheezing through 3 years of age and (2) third trimester maternal 25-OH(D) levels. Analysis of infant outcomes included 806 infants, 218 of whom developed asthma by age 3. The proportion of infants with asthma or recurrent wheeze was 24% in the 4400 IU group versus 30% in the 400 IU group (difference, -6%; 95% CI, -30% to 18%). There were no differences in the proportion of infants experiencing eczema or lower respiratory tract infections.
Section Summary: Asthma
Results of RCTs have reported mixed findings with respect to the effect of vitamin D supplementation on asthma outcomes. Populations included in studies varied by baseline vitamin D deficiency levels, administration of vitamin D, and the severity of asthma. In general, patients were not selected based on low baseline 25(OH)D level. While there is some evidence that vitamin D supplementation reduces the rate of asthma exacerbations, it is unclear if baseline 25(OH)D level is related to treatment benefit. The current evidence is insufficient to determine the effect of vitamin D supplementation on asthma outcomes.

Multiple Sclerosis
Three systematic reviews have examined the effect of vitamin D supplementation in patients with multiple sclerosis.[48][49][50]

Reviewers described 6 RCTs, all of which were small (n<100). Patient follow-up ranged from 6 months to 2 years, and dosing and administration of vitamin D varied. None of the trials reported improvement in MS relapse rates; most trials showed no effect of vitamin D on any of the surrogate or clinical outcomes. Only 1 trial reported improvement in magnetic resonance imaging of lesions in the vitamin D supplementation group. The evidence for vitamin D supplementation in MS is poor.

Overall Mortality
A number of meta-analyses of RCTs of vitamin D supplementation have examined the benefit of vitamin D supplementation on overall mortality. Table 6 summarizes the most recent meta-analyses. The individual studies ranged in size from fewer than 100 to several thousand patients. No significant heterogeneity was reported for these trials.

The most relevant information comes from a meta-analysis of patients with vitamin D deficiency by LeBlanc et al (2015).[51]

This report included 11 studies and found a marginally significant reduction in overall mortality, with a CI that approached 1.0. When the subgroup analysis was performed, it became apparent that most of the benefit was specific to institutionalized patients—whereas, in community-dwelling patients, the data revealed no reduction in mortality.

The AHRQ report by Newberry et al (2014),[28] assessing the health effects of vitamin D supplementation, updated the original 2007 report. A quantitative synthesis of all trials was not performed in the 2014 update. Rather reviewers identified areas where the new trials might change previous conclusions. Their main conclusions were that the results did not support a benefit on overall mortality associated with vitamin D supplementation. No important trials identified in the update would potentially change this conclusion.

For meta-analyses including RCTs that treated all patients with vitamin D, most analyses have not shown a significant reduction in mortality. The single analysis that did show a significant reduction was that by Chowdhury et al (2014), who reported a marginally significant result for vitamin D3 supplementation but not for vitamin D2 supplementation.[52]
**Table 6.** Results of Systematic Reviews of RCTs Assessing the Impact of Vitamin D Supplementation on Mortality

<table>
<thead>
<tr>
<th>Study</th>
<th>Outcome</th>
<th>No. of Studies</th>
<th>No. of Participants</th>
<th>I², %a</th>
<th>RR for Outcome (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with vitamin D deficiency</td>
<td>Mortality (all patients)</td>
<td>11</td>
<td>4126</td>
<td>0</td>
<td>0.83 (0.70 to 0.99)</td>
</tr>
<tr>
<td>Leblanc et al (2015)</td>
<td>Mortality (noninstitutionalized patients)</td>
<td>8</td>
<td>2947</td>
<td>0</td>
<td>0.93 (0.73 to 1.18)</td>
</tr>
<tr>
<td>All patients</td>
<td>Mortality (vitamin D3)</td>
<td>14</td>
<td>13,367</td>
<td>0</td>
<td>0.89 (0.80 to 0.99)</td>
</tr>
<tr>
<td>Chowdhury et al (2014)</td>
<td>Mortality (vitamin D2)</td>
<td>8</td>
<td>17,079</td>
<td>0</td>
<td>1.04 (0.97 to 1.11)</td>
</tr>
<tr>
<td>Bjelakovic et al (2011)</td>
<td>Mortality (vitamin D3)</td>
<td>9</td>
<td>12,824</td>
<td>0</td>
<td>0.91 (0.82 to 1.02)</td>
</tr>
<tr>
<td>Palmer et al (2009)</td>
<td>Mortality (CKD-RD)</td>
<td>5</td>
<td>233</td>
<td>0</td>
<td>1.34 (0.34 to 5.24)</td>
</tr>
<tr>
<td>Palmer et al (2009)</td>
<td>Mortality (CKD)</td>
<td>4</td>
<td>477</td>
<td>0</td>
<td>1.40 (0.38 to 5.15)</td>
</tr>
</tbody>
</table>

CI: confidence interval; CKD: chronic kidney disease; CKD-RD: chronic kidney disease on renal dialysis; RCT: randomized controlled trial; RR: relative risk. a Heterogeneity value.

**Section Summary: Overall Mortality**

Evidence from a number of systematic reviews and meta-analyses does not support a benefit on overall mortality for the general, noninstitutionalized population. Populations included in the studies varied by baseline vitamin D deficiency and administration of vitamin D.

**SUMMARY OF EVIDENCE**

For individuals who are asymptomatic without conditions or risk factors for which vitamin D treatment is recommended who receive testing of vitamin D levels, the evidence includes no randomized controlled trials (RCTs) of clinical utility (ie, evidence that patient care including testing vitamin D levels vs care without testing vitamin D levels improves outcomes). Relevant outcomes are overall survival, test validity, symptoms, morbid events, and treatment-related morbidity. Indirect evidence of the potential utility of testing includes many RCTs and systematic reviews of vitamin D supplementation. There is a lack of standardized vitamin D testing strategies and cutoffs for vitamin D deficiency are not standardized or evidence-based. In addition, despite the large quantity of evidence, considerable uncertainty remains about the beneficial health effects of vitamin D supplementation. Many RCTs have included participants who were not vitamin D deficient at baseline and did not stratify results by baseline 25-hydroxyvitamin D level. Nonwhite race/ethnic groups are underrepresented in RCTs but have increased risk of vitamin D deficiency. For skeletal health, there may be a small effect of vitamin D supplementation on falls, but there does not appear to be an impact on reducing fractures for the general population. The effect on fracture reduction may be significant in elderly women, and with higher doses of vitamin D. For patients with asthma, there may be a reduction in severe exacerbations with vitamin D supplementation, but there does not appear to be an effect on other asthma outcomes. For overall mortality, there is also no benefit to the general population. RCTs...
evaluating extraskeletal, cancer, cardiovascular, and multiple sclerosis outcomes have not reported a statistically significant benefit for vitamin D supplementation. Although vitamin D toxicity and adverse events appear to be rare, few data on risks have been reported. The evidence is insufficient to determine the effects of the technology on health outcomes.

**PRACTICE GUIDELINES AND POSITION STATEMENTS**

**Endocrine Society**
The Endocrine Society (2011) published clinical practice guidelines on the evaluation, treatment, and prevention of vitamin D deficiency.[55]

The following recommendations were made regarding testing vitamin D levels:

- 25-hydroxyvitamin D serum level testing is recommended: “to evaluate vitamin D status only in patients who are at risk of deficiency.” The guideline did not recommend screening of individuals not at risk of vitamin D deficiency.
- 1,25-dihydroxyvitamin D testing was not recommended to evaluate vitamin D status. However, the guideline did recommend monitoring calcitriol levels under certain conditions.

**American College of Obstetrics and Gynecology**
The American College of Obstetrics and Gynecology issued a committee opinion (2011, reaffirmed 2017) on the testing of vitamin D levels and vitamin D supplementation in pregnant women.[56]

The following recommendation was made concerning testing vitamin D levels:

“At this time there is insufficient evidence to support a recommendation for screening all pregnant women for vitamin D deficiency. For pregnant women thought to be at increased risk of vitamin D deficiency, maternal serum 25-hydroxyvitamin D levels can be considered and should be interpreted in the context of the individual clinical circumstance. When vitamin D deficiency is identified during pregnancy, most experts agree that 1,000-2,000 international units per day of vitamin D is safe.”

**American Academy of Family Physicians**
The American College of Obstetrics and Gynecology issued a committee opinion (2011, reaffirmed 2017) on the testing of vitamin D levels and vitamin D supplementation in pregnant women.[56]

The following recommendation was made concerning testing vitamin D levels:

“At this time there is insufficient evidence to support a recommendation for screening all pregnant women for vitamin D deficiency. For pregnant women thought to be at increased risk of vitamin D deficiency, maternal serum 25-hydroxyvitamin D levels can be considered and should be interpreted in the context of the individual clinical circumstance. When vitamin D deficiency is identified during pregnancy, most experts agree that 1,000-2,000 international units per day of vitamin D is safe.”

**U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS**
The U.S. Preventive Services Task Force published a recommendation in 2014[59] and associated guidelines in 2015[60] on vitamin D screening. The Task Force concluded that the current evidence was insufficient to assess the balance of benefits and harms of screening for vitamin D.
deficiency in asymptomatic individuals (grade I [insufficient evidence]). An update of the 2014 recommendation is currently in progress.

**ONGOING AND UNPUBLISHED CLINICAL TRIALS**

Some currently unpublished trials that might influence this review are listed in Table 7.

**Table 7. Summary of Key Trials**

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ongoing</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01169259</td>
<td>Vitamin D and Omega-3 Trial (VITAL)</td>
<td>25,871</td>
<td>Nov 2018 (ongoing)</td>
</tr>
<tr>
<td>NCT01490502</td>
<td>A Randomized Controlled Trial of Vitamin D Supplementation in Multiple Sclerosis (VIDAMS)</td>
<td>172</td>
<td>Mar 2019</td>
</tr>
<tr>
<td>NCT00920621</td>
<td>Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART)</td>
<td>876</td>
<td>Jun 2019</td>
</tr>
<tr>
<td>NCT02166333</td>
<td>Vitamin D Supplements to Prevent Falls in Older Adults: A Dose-Response Trial (STURDY)</td>
<td>1200</td>
<td>Mar 2020</td>
</tr>
<tr>
<td><strong>Unpublished</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01153568</td>
<td>Vitamin D and Osteoporosis Prevention in Elderly African American Women: A 4-year Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Vitamin D Status in Elderly African American Women</td>
<td>260</td>
<td>Oct 2016 (completed)</td>
</tr>
<tr>
<td>NCT02424552</td>
<td>EVITA Trial: Effect of Vitamin D as add-on Therapy for Vitamin D Insufficient Patients With Severe Asthma: a Randomized, Double-blind, Placebo-controlled Trial</td>
<td>54</td>
<td>Mar 2017 (terminated)</td>
</tr>
<tr>
<td>NCT02750293</td>
<td>The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors in Subjects With Low Serum 25-hydroxyvitamin D Levels (D-COR)</td>
<td>411</td>
<td>Sep 2017 (completed)</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

**CODING**

The following codes for treatment and procedures applicable to this policy are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

**CPT/HCPCS**

- 82306  Vitamin D; 25 hydroxy, includes fraction(s), if performed
- 82652  Dihydroxyvitamin D, 1, 25 dihydroxy, includes fraction(s), if performed
- 0038U  Vitamin D, 25 hydroxy D2 and D3, by LCMS/MS, serum microsample, quantitative

**ICD-10 Diagnoses**

- D71  Functional disorders of polymorphonuclear neutrophils
- E20.0  Idiopathic hypoparathyroidism
- E20.1  Pseudohypoparathyroidism
- E20.8  Other hypoparathyroidism
- E21.0  Primary hyperparathyroidism
- E21.1  Secondary hyperparathyroidism, not elsewhere classified
E21.2       Other hyperparathyroidism  
E21.4       Other specified disorders of parathyroid gland  
E55.0       Rickets, active  
E55.9       Vitamin D deficiency, unspecified  
E83.51      Hypocalcemia  
E83.52      Hypercalcemia  
E83.59      Other disorders of calcium metabolism  
K70.0       Alcoholic fatty liver  
K70.10      Alcoholic hepatitis without ascites  
K70.11      Alcoholic hepatitis with ascites  
K70.2       Alcoholic fibrosis and sclerosis of liver  
K70.30      Alcoholic cirrhosis of liver without ascites  
K70.31      Alcoholic cirrhosis of liver with ascites  
K70.40      Alcoholic hepatic failure without coma  
K70.41      Alcoholic hepatic failure with coma  
K71.0       Toxic liver disease with cholestasis  
K71.10      Toxic liver disease with hepatic necrosis, without coma  
K71.11      Toxic liver disease with hepatic necrosis, with coma  
K71.2       Toxic liver disease with acute hepatitis  
K71.3       Toxic liver disease with chronic persistent hepatitis  
K71.4       Toxic liver disease with chronic lobular hepatitis  
K71.50      Toxic liver disease with chronic active hepatitis without ascites  
K71.51      Toxic liver disease with chronic active hepatitis with ascites  
K71.6       Toxic liver disease with hepatitis, not elsewhere classified  
K71.7       Toxic liver disease with fibrosis and cirrhosis of liver  
K71.8       Toxic liver disease with other disorders of liver  
K72.10      Chronic hepatic failure without coma  
K72.11      Chronic hepatic failure with coma  
K73.0       Chronic persistent hepatitis, not elsewhere classified  
K73.1       Chronic lobular hepatitis, not elsewhere classified  
K73.2       Chronic active hepatitis, not elsewhere classified  
K73.8       Other chronic hepatitis, not elsewhere classified  
K74.0       Hepatic fibrosis  
K74.1       Hepatic sclerosis  
K74.2       Hepatic fibrosis with hepatic sclerosis  
K74.3       Primary biliary cirrhosis  
K74.4       Secondary biliary cirrhosis  
K74.60      Unspecified cirrhosis of liver  
K74.69      Other cirrhosis of liver  
K75.3       Granulomatous hepatitis, not elsewhere classified  
K75.4       Autoimmune hepatitis  
K75.81      Nonalcoholic steatohepatitis (NASH)  
K75.89      Other specified inflammatory liver diseases  
K76.0       Fatty (change of) liver, not elsewhere classified  
K76.1       Chronic passive congestion of liver  
K76.2       Central hemorrhagic necrosis of liver  
K76.3       Infarction of liver  
K76.4       Peliosis hepatitis  

Contains Public Information
K76.5 Hepatic veno-occlusive disease
K76.7 Hepatorenal syndrome
K76.81 Hepatopulmonary syndrome
K76.89 Other specified diseases of liver
K77 Liver disorders in diseases classified elsewhere
K83.01 Primary sclerosing cholangitis
K83.09 Other cholangitis
K83.1 Obstruction of bile duct
K83.2 Perforation of bile duct
K83.3 Fistula of bile duct
K83.4 Spasm of sphincter of Oddi
K83.5 Biliary cyst
K83.8 Other specified diseases of biliary tract
K90.0 Celiac disease
K90.1 Tropical sprue
K90.2 Blind loop syndrome, not elsewhere classified
K90.3 Pancreatic steatorrhea
K90.49 Malabsorption due to intolerance, not elsewhere classified
K90.81 Whipple's disease
K90.89 Other intestinal malabsorption
K90.9 Intestinal malabsorption, unspecified
K91.2 Postsurgical malabsorption, not elsewhere classified
M80.011A-S Age-related osteoporosis with current pathologic fracture, right shoulder
M80.012A-S Age-related osteoporosis with current pathologic fracture, left shoulder
M80.021A-S Age-related osteoporosis with current pathologic fracture, right humerus
M80.022A-S Age-related osteoporosis with current pathologic fracture, left humerus
M80.031A-S Age-related osteoporosis with current pathologic fracture, right forearm
M80.032A-S Age-related osteoporosis with current pathologic fracture, left forearm
M80.041A-S Age-related osteoporosis with current pathologic fracture, right hand
M80.042A-S Age-related osteoporosis with current pathologic fracture, left hand
M80.051A-S Age-related osteoporosis with current pathologic fracture, right femur
M80.052A-S Age-related osteoporosis with current pathologic fracture, left femur
M80.061A-S Age-related osteoporosis with current pathologic fracture, right lower leg
M80.062A-S Age-related osteoporosis with current pathologic fracture, left lower leg
M80.071A-S Age-related osteoporosis with current pathologic fracture, right ankle and foot
M80.072A-S Age-related osteoporosis with current pathologic fracture, left ankle and foot
M80.08XA-S Age-related osteoporosis with current pathologic fracture, vertebra(e)
M80.811A-S Other osteoporosis with current pathologic fracture, right shoulder
M80.812A-S Other osteoporosis with current pathologic fracture, left shoulder
M80.821A-S Other osteoporosis with current pathologic fracture, right humerus
M80.822A-S Other osteoporosis with current pathologic fracture, left humerus
M80.831A-S Other osteoporosis with current pathologic fracture, right forearm
M80.832A-S Other osteoporosis with current pathologic fracture, left forearm
M80.841A-S Other osteoporosis with current pathologic fracture, right hand
M80.842A-S Other osteoporosis with current pathologic fracture, left hand
M80.851A-S Other osteoporosis with current pathologic fracture, right femur
M80.852A-S Other osteoporosis with current pathologic fracture, left femur
M80.861A-S Other osteoporosis with current pathologic fracture, right lower leg
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>M80.862A-S</td>
<td>Other osteoporosis with current pathological fracture, left lower leg</td>
</tr>
<tr>
<td>M80.871A-S</td>
<td>Other osteoporosis with current pathological fracture, right ankle and foot</td>
</tr>
<tr>
<td>M80.872A-S</td>
<td>Other osteoporosis with current pathological fracture, left ankle and foot</td>
</tr>
<tr>
<td>M80.88XA-S</td>
<td>Other osteoporosis with current pathological fracture, vertebra(e)</td>
</tr>
<tr>
<td>M81.0</td>
<td>Age-related osteoporosis without current pathological fracture</td>
</tr>
<tr>
<td>M81.6</td>
<td>Localized osteoporosis [Lequesne]</td>
</tr>
<tr>
<td>M81.8</td>
<td>Other osteoporosis without current pathological fracture</td>
</tr>
<tr>
<td>M83.0</td>
<td>Puerperal osteomalacia</td>
</tr>
<tr>
<td>M83.1</td>
<td>Senile osteomalacia</td>
</tr>
<tr>
<td>M83.2</td>
<td>Adult osteomalacia due to malabsorption</td>
</tr>
<tr>
<td>M83.3</td>
<td>Adult osteomalacia due to malnutrition</td>
</tr>
<tr>
<td>M83.4</td>
<td>Aluminum bone disease</td>
</tr>
<tr>
<td>M83.5</td>
<td>Other drug-induced osteomalacia in adults</td>
</tr>
<tr>
<td>M83.8</td>
<td>Other adult osteomalacia</td>
</tr>
<tr>
<td>M85.811</td>
<td>Other specified disorders of bone density and structure, right shoulder</td>
</tr>
<tr>
<td>M85.812</td>
<td>Other specified disorders of bone density and structure, left shoulder</td>
</tr>
<tr>
<td>M85.821</td>
<td>Other specified disorders of bone density and structure, right upper arm</td>
</tr>
<tr>
<td>M85.822</td>
<td>Other specified disorders of bone density and structure, left upper arm</td>
</tr>
<tr>
<td>M85.831</td>
<td>Other specified disorders of bone density and structure, right forearm</td>
</tr>
<tr>
<td>M85.832</td>
<td>Other specified disorders of bone density and structure, left forearm</td>
</tr>
<tr>
<td>M85.841</td>
<td>Other specified disorders of bone density and structure, right hand</td>
</tr>
<tr>
<td>M85.842</td>
<td>Other specified disorders of bone density and structure, left hand</td>
</tr>
<tr>
<td>M85.851</td>
<td>Other specified disorders of bone density and structure, right thigh</td>
</tr>
<tr>
<td>M85.852</td>
<td>Other specified disorders of bone density and structure, left thigh</td>
</tr>
<tr>
<td>M85.861</td>
<td>Other specified disorders of bone density and structure, right lower leg</td>
</tr>
<tr>
<td>M85.862</td>
<td>Other specified disorders of bone density and structure, left lower leg</td>
</tr>
<tr>
<td>M85.871</td>
<td>Other specified disorders of bone density and structure, right ankle and foot</td>
</tr>
<tr>
<td>M85.872</td>
<td>Other specified disorders of bone density and structure, left ankle and foot</td>
</tr>
<tr>
<td>M85.88</td>
<td>Other specified disorders of bone density and structure, other site</td>
</tr>
<tr>
<td>M85.89</td>
<td>Other specified disorders of bone density and structure, multiple sites</td>
</tr>
<tr>
<td>M85.9</td>
<td>Disorder of bone density and structure, unspecified</td>
</tr>
<tr>
<td>N18.3</td>
<td>Chronic kidney disease, stage 3 (moderate)</td>
</tr>
<tr>
<td>N18.4</td>
<td>Chronic kidney disease, stage 4 (severe)</td>
</tr>
<tr>
<td>N18.5</td>
<td>Chronic kidney disease, stage 5</td>
</tr>
<tr>
<td>N18.6</td>
<td>End stage renal disease</td>
</tr>
<tr>
<td>Q78.0</td>
<td>Osteogenesis imperfecta</td>
</tr>
<tr>
<td>Q78.2</td>
<td>Osteopetrosis</td>
</tr>
<tr>
<td>Z59.3</td>
<td>Problems related to living in residential institution</td>
</tr>
<tr>
<td>Z79.52</td>
<td>Long term (current) use of systemic steroids</td>
</tr>
<tr>
<td>Z79.899</td>
<td>Other long term (current) drug therapy</td>
</tr>
</tbody>
</table>

**REVISIONS**

**03-08-2010**  
Updated Description section

In Coding Section:
- Removed CPT code: 82307 (effective 01/01/2010)
- Updated wording for CPT codes: 82306, 82652 (effective 01/01/2010)

Updated References
<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
</table>
| 10-26-2010| Updated Description section<br>In Policy section:<br>▪ To emphasize the need for recommended vitamin D supplementation prior to testing, revised the wording from: "A. Conditions for which testing for vitamin D deficiency may be considered medically necessary, include:" to: "A. Testing for vitamin D deficiency is considered not medically necessary except when: 1. The recommended vitamin D supplementation is being taken AND 2. One of the following conditions is present:"
| 01-28-11  | Updated Description section. Updated Reference section. In Coding section:<br>▪ Updated diagnosis coding from 345.0-345.9 to 345.00-345.91 |
| 03-28-2011| Updated the Description section.<br>In Coding section:<br>▪ Addition of diagnosis codes: 252.1 and 775.4. |
| 09-29-2011| Updated the Description section.<br>In the Policy Language section:<br>▪ In Item A, #2, h, added "oral anti-fungals,"
▪ In Item A, #2, added the following:<o ▪ "o. muscle weakness<br>o. p. history of falls<br>q. history of vitamin D deficiency"
| 12-20-2011| Updated the Description section.<br>In the Coding section:<br>▪ Added the following diagnosis codes: 135, 263-263.8, 268.9, 275.41, 275.49, 555.0-555.9, 556.0, 556.1, 556.2, 556.3, 556.6, 556.8, 556.9, 577.1, 579.0-579.9, 728.87 |
| 02-05-2014| Policy reviewed.<br>In Policy section:<br>▪ In Item A, 2, inserted "r. Post transplant"
| 10-01-2015| Policy published 03-25-2016. Effective 10-01-2015 with ICD-10 coding implementation.<br>In Coding section:<br>▪ Added ICD-10 code Z91.81|
| 06-10-2016| Updated Description section.<br>In Policy section:
In Item A, removed "is", "not", and "except", and added "may be", "in patients with signs and/or symptoms of vitamin D deficiency or toxicity (see Policy Guidelines)", and "one of the high-risk factors is present" to read "Testing for Vitamin D deficiency may be considered medically necessary in patients with signs and/or symptoms of vitamin D deficiency or toxicity (see Policy Guidelines) when one of the high-risk factors is present;"

Removed previous Item A 1, "The recommended vitamin D supplementation is being taken AND"

Removed previous Item A 2, "One of the following conditions is present"

Removed previous Item A 2 c, "hyperthyroidism"

Removed previous Item A 2 e, "heritable disorders of Vitamin D metabolism"

Removed previous Item A 2 i, "obesity"

Removed previous Item A 2 m, "phosphaturia"

Removed previous Item A 2 o, "muscle weakness"

Removed previous Item A 2 p, "history of falls"

In current Item A 1, added ", stage ≥3" to read "chronic kidney disease, stage ≥3"

In current Item A 2, removed "disorder" and added "diseases" to read "granulomatous diseases"

In current Item A 3, removed "hyperparathyroidism" and added "parathyroid disorders"

In current Item A 4, removed "liver failure" and added "cirrhosis/chronic liver disease"

In current Item A 5, added "states" to read "malabsorption states"

In current Item A 6, removed "(oral antifungals, AIDS medications)" and added "chronic use of" to read "chronic use of anticonvulsant medications or corticosteroids"

In current Item A 11, removed "history of vitamin D deficiency" and added "vitamin D deficiency, in replacement"

Added Item A 12, "hypo- or hypercalcemia"

Added Item A 13, "obstructive jaundice/biliary tract disease"

Added Item A 14, "osteogenesis imperfecta"

Added Item A 15, "osteosclerosis/osteopetrosis"

Added Item B, Item B 1, and Item B 2, "Testing vitamin D levels in asymptomatic patients may be considered medically necessary in the following patient populations:
1. Individuals who have risk factors for vitamin D deficiency (as listed in Item A above)
2. Institutionalized patients (see Policy Guidelines)"

Added Item C, "Testing vitamin D levels in asymptomatic patients is considered not medically necessary when the above criteria are not met."

Added Policy Guidelines

Added Rationale section.

In Coding section:

Removed ICD-10 codes B20, D86.0, D86.1, D86.2, D86.3, D86.81, D86.82, D86.83, D86.84, D86.85, D86.86, D86.87, D86.89, D86.9, E05.00, E05.01, E05.10, E05.11, E05.20, E05.21, E44.0, E44.1, E45, E64.3, E66.01, E66.09, E66.1, E66.8, E83.30, E83.31, E83.32, E83.39, E84.0, E84.19, E84.8, E84.9, G40.001, G40.009, G40.011, G40.019, G40.101, G40.109, G40.111, G40.119, G40.201, G40.209, G40.211, G40.219, G40.301, G40.309, G40.401, G40.409, G40.411, G40.419, G40.501, G40.509, G40.801, G40.802, G40.811, G40.812, G40.813, G40.814, G40.821, G40.822, G40.823, G40.824, G40.825, G40.901, G40.909, G40.911, G40.919, G40.A01, G40.A09, G40.A11, G40.A19, G40.B01, G40.B09, G40.B11, G40.B19, K50.00, K50.018, K50.019, K50.10, K50.118, K50.119, K50.80, K50.818, K50.819, K50.90, K50.918, K50.919, K51.00, K51.018, K51.019, K51.20, K51.218, K51.219, K51.30, K51.318, K51.319, K51.80, K51.818, K51.819, K51.90, K51.918, K51.919, K73.9, K86.0, K86.1, K90.9, M62.81, M89.9, M94.9, N18.2, P71.0, P71.1, P71.2, P71.3, P71.4, P71.8, P71.9, R17, Z91.81

Added ICD-10 codes E20.0, E20.1, E20.8, E21.4, E83.52, K71.0, K71.10, K71.11, K71.2, K71.3, K71.4, K71.50, K71.51, K71.6, K71.7, K71.8, K72.10, K72.11, K74.0,
REFERENCES


13. Theodoratou E, Tzoulaki I, Zgaga L, et al. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ. Apr 01 2014;348:g2035. PMID 24690624
20. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. May 12 2010;303(18):1815-1822. PMID 20460620


Other References
1. Blue Cross and Blue Shield of Kansas Internal Medicine Liaison Committee, January 2010; August 2013; August 2014; February 2016; June 2017.
3. Blue Cross and Blue Shield of Kansas Family Practice Liaison Committee, July 2014.